Aim: Mitochondrial autophagy (mitophagy) clears damaged mitochondria and attenuates ischemic neuronal injury. Urolithin A (Uro-A) activates mitophagy in mammal cells and Caenorhabditis elegans. We explored neuroprotection of Uro-A against ischemic neuronal injury. Furthermore, Uro-A-conferred protection was abolished by 3-methyladenine, suggesting the requirement of autophagy for neuroprotection. However, mitophagy was not further activated by Uro-A. Instead, Uro-A attenuated OGD/R-induced ER stress, which was abolished by 3-methyladenosine. Additionally, neuroprotection was reversed by ER stress inducer.
| INTRODUC TI ON
Ischemic stroke is one of the leading causes of death and disability worldwide. 1 The pathological mechanisms underlying ischemic neuronal injury remain not fully elucidated and thus attribute to the shortage of effective pharmacological approaches for stroke therapy. 2, 3 Autophagy is an intracellular catabolic process that turnover of protein and organelles in lysosomes. 4 Autophagy is activated in ischemic neurons. Several lines of evidence indicated that autophagy protects against ischemic neuronal injury. 5, 6 Autophagy eliminates damaged mitochondria (or terms mitophagy) and subsequently prevents mitochondria-dependent cell apoptosis and attenuates ischemia/reperfusion-induced brain injury. 8, 9 Conversely, reinforced mitophagy shows additional neuroprotection against ischemic injury. 10, 11 These findings indicate that mitophagy activation may hold promise as a potential therapeutic strategy against ischemic brain injury.
Urolithins are naturally occurring polyphenols that are produced by human gut microbiota from ellagitannins and ellagic acid.
Previous studies have shown that urolithins have multiple biological activities including antioxidant, anticancer, anti-inflammatory, and antimicrobial properties. 15, 16 Among other urolithins, urolithin A (Uro-A) was found to induce autophagy in human colorectal cancer cells and macrophages. 20, 21 More recently, Uro-A was demonstrated to induce mitophagy in Caenorhabditis elegans and murine cell lines. 22 However, whether Uro-A might activate mitophagy and confer neuroprotection against ischemic injury has not been tested.
| MATERIAL S AND ME THODS

| Animals
Male C57BL/6 mice weighing 22-25 g were used. All experiments were approved by and conducted in accordance with the ethical guidelines of the Zhejiang University Animal Experimentation
Committee and were in complete compliance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals. Every effort was made to minimize any pain or discomfort, and the minimum number of animals was used.
| Middle cerebral artery occlusion model and drug treatments
Mice were anesthetized by inhalation of isoflurane. Focal cerebral ischemia was induced by Middle cerebral artery occlusion (MCAO)
as described previously. 23 See Method S1 for more details.
Uro-A (Toronto Research Chemical, Cat No. U847000) was dissolved in DMSO (50 mg/mL) and further diluted with saline immediately before intraperitoneal (ip) injections. Mice were given an intraperitoneal injection of 2.5 or 5.0 mg/kg of Uro-A as previously described, 24, 25 for 24 hours and 1 hour before surgery. Mice were grouped into a sham, sham + Uro-A, MCAO, and MCAO + Uro-A groups. Mice in the sham group were injected with the same volume of saline.
| Infarct analysis
Infarct volume was determined at 24 hours after surgery by staining with 2, 3, 5-triphenyltetrazolium hydrochloride (TTC, 0.25%).
Infarcted areas were analyzed using Image-Pro Plus 7.0 and determined by the indirect method, which corrected for edema. The percentage of corrected infarct volume was calculated by dividing the infarct volume by the total contralateral hemispheric volume, and this ratio was then multiplied by 100. 
| Behavioral measurements
Neurological deficit scores were evaluated at 24 hours of reperfusion as followed: 0, no deficit; 1, flexion of the contralateral forelimb on lifting of the whole animal by the tail; 2, circling to the contralateral side; 3, falling to the contralateral side; and 4, no spontaneous motor activity.
| Cell culture and oxygen-glucose deprivation/ reperfusion procedures
The primary cortical neuronal culture was performed as described.
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See Method S1 for more details.
Mouse neuroblastoma neuro-2a (N2a, ATCC ® CCL-131™) cells were routinely cultured in DMEM (Gibco) containing 10% fetal bovine serum (FBS, Gibco), 10 U/mL penicillin, and 10 U/mL streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . N2a cells were differentiated in all experiments as following protocol. Briefly, one day after seeding, the culture medium was replaced with differentiation medium (DM), DMEM without FBS and supplemented with N-2 supplement (100X Gibco) and cells were further incubated for 24 hours to induce differentiation.
The OGD/R model was employed here to mimic ischemia/reperfusion-like conditions in vitro as we previously used. 28 See Method S1 for more details. The 2.5 mmol/L of 3-MA and 10 µmol/L of chloroquine (CQ) were dissolved in normal culture medium and added to the cells at the onset of reperfusion.
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autophagy/mitophagy, cerebral ischemia, endoplasmic reticulum stress, neuroprotection, urolithin A 2 hours and then exposed to OGD 4 hours and 1.5 hours, respectively, and reperfusion for 24 hours in the presence of Uro-A as previously described. 8 Cell viability was estimated by using dye 3-4,5-dimethyl thiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT, Sigma). The MTT solution was added into each well (5 mg/mL), and the plates were incubated for 2 hours at 37°C. The viability was then measured by evaluating the absorbance at 570 nm. Normal cells were used as the control group, and the cell viability of the control group was assumed to be 100%.
| Cell viability determination by MTT assay
| Cell demise determined by lactate dehydrogenase assay
Previous findings have shown that the activity of LDH from damaged cells is proportional to the number of damaged neurons. 30, 31 After exposure to OGD/R, a 50 µL of medium was removed and the amount of LDH leakage from the cells was determined using the 
| Plasmids and transfection
Mito-green fluorescent protein (GFP) was purchased from (Clontech, The N2a cells were transfected using jet PRIME Reagent (Polyplus transfection) at 24 hours before further experiments.
| Confocal microscopy and image analysis
For live microscopy examination, N2a cells and primary neurons were seeded onto a poly-l-lysine-treated glass bottom dish (In Vitro Scientific, D35-20-0-N) transfected with mCherry-LC3
and Mito-GFP. After OGD, N2a cells and primary neurons were treated with 10 and 30 µmol/L of Uro-A and re-perfused for 3 hours. Optical z series images were obtained by using a confocal microscope (Leica Microsystems, Germany). The number and area occupied by LC3 puncta and Mander's overlap efficiency was measured and analyzed as described by Image-Pro Plus 7.0 software. 32 For each condition, a total of 50 cells were analyzed.
| Quantitative real-time polymerase chain reaction
To detect the mRNA levels of ATF6 and C/EBP homologous protein 
| Western blot analysis
Protein extraction, quantification, and immunoblotting were performed as described previously. 13 See Method S1 for more details.
| Statistical analysis
All the data were performed using Graph Pad Prism 7 and expressed as mean ± SD. One-way analysis of variance was used to perform statistical analysis. P < 0.05 was considered statistically significant.
| RE SULTS
| Uro-A inhibited OGD/R-induced cell injury in
N2a cells and primary cultured neurons
Cell viability assays (MTT) indicated that OGD/R treatment in both 
| Uro-A reinforced ischemic reperfusioninduced autophagy both in vitro and in vivo
To examine whether Uro-A activates autophagy in ischemic neuronal cells, we quantified the LC3-positive puncta number and size, which were widely used to indicate autophagosome formation. 33 By transfecting mCherry-LC3 to N2a cells, we found significantly increased quantity of mCherry-LC3-positive puncta in N2a cells after 3 hour of reperfusion, indicating autophagy activation by ischemia, which was in line with previous studies. Figure 2I ). Collectively, these results suggested that Uro-A activated autophagy and promoted autophagosome maturation in both ischemic neuronal cells and ischemic brains.
| Autophagy is required for Uro-A conferred neuroprotection
To verify whether autophagy induction is involved in the neuroprotective effect of Uro-A, we incubated the N2a cells and primary cultured neurons with 10 µmol/L of Uro-A in the presence or absence of autophagy inhibitor 3-MA during OGD/R, at which the most intense autophagy flux was observed. We found that co-incubation of 3-MA significantly abolished the neuroprotection of Uro-A by reversing the increase in cell viability both in N2a cells and primary cultured neurons ( Figure 3A and B). Inconsistent with the results of cell viability, we found that attenuated LDH leakage with Uro-A treatment was significantly abolished by 3-MA ( Figure 3C and D) . Overall, these data indicated that the autophagy activation was required for the neuroprotective effect of Uro-A.
| Uro-A does not induce mitophagy both in ischemic neuronal cells and in vivo
Previous research showed that Uro-A induced mitophagy in mammal cells and C elegans. 22 In addition, our previous studies indicated that autophagy conferred its neuroprotection by promoting mitophagy.
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Here we found Uro-A-activated autophagy involved in the neuroprotection, and we further asked whether Uro-A enhanced mitophagy.
To this end, we transfected both N2a cells and primary cultured neurons with mito-GFP and mCherry-LC3 to visualize mitochondria and autophagosomes, respectively. To our surprise, Uro-A alone did not induce mitophagy in both intact N2a cells and neurons at the concentration of either 10 or 30 μM, indicated by similar mito-GFP-positive area to control group. Consistent with our previous studies, OGD/R significantly reduced the area of mitochondria labeled by mito-GFP in both N2a cells and neurons, which suggested mitophagy activation. Figure 4I ). These data indicated that Uro-A did not induce mitophagy in both ischemia/reperfusioninjured neuronal cells and mice.
| Uro-A represses the ER stress by activation of autophagy both in vitro and in vivo
Endoplasmic reticulum stress was activated in ischemic brains and resulted in neuronal demise. 34 As a consequence, autophagy helps to alleviate ER stress. 35, 36 We thus hypothesize that Uro-A might suppress ER stress by activating autophagy. We determined mRNA levels of ATF6 and CHOP both in vitro and in vivo, which reflected the extension of ER stress. 37, 38 Our data indicated that both ATF6
and CHOP were significantly increased after OGD/R Of note, treatment with Uro-A (3-30 µmol/L) significantly decreased OGD/Rinduced upregulations of ATF6 and CHOP in a dose-dependent manner ( Figure 5A and B). Consistent with the changes in ER stress in N2a cells, quantitative PCR confirmed the upregulation of ATF6 and CHOP after MCAO both which were substantially inhibited by Uro-A ( Figure 5C and D). These data suggested that Uro-A alleviated ischemia-induced ER stress both in vitro and in vivo.
To confirm the involvement of autophagy in ER stress alleviation with Uro-A treatment, we blocked autophagy with 3-MA. The results
showed that compared with Uro-A treatment alone, 3-MA significantly reversed the mRNA levels of ATF6 and CHOP, suggesting autophagy was involved in alleviating ER stress by Uro-A in OGD/R-treated neuronal cells ( Figure 5E and F) . Furthermore, we examined whether ER stress alleviation contributed to the neuroprotective effect of Uro-A against ischemia. To this end, an ER stress activator, thapsigargin, was added to N2a cells alone or with Uro-A during reperfusion. We found thapsigargin significantly abolished the neuroprotection of Uro-A as reflected by a remarkable reduction of cell viability. Thapsigargin alone showed no impact on cell viability, which excluded the cytotoxicity in this concentration ( Figure 5G ). Taken together, these results indicated that Uro-A alleviated OGD/R-induced ER stress by activating autophagy and thus protected neuronal cells from ischemic injury.
| Uro-A reduced acute ischemic brain injury in mice
The neuroprotective effect of Uro-A against ischemia was further investigated in vivo by using a temporary middle cerebral artery occlusion (MCAO) model in mice. The results showed that MCAO induced 29.8 ± 3.9% of infarct volumes and 3.0 ± 0.7% of neurological deficit score in mice. The 2.5 and 5.0 mg/kg of Uro-A treatments significantly decreased the volume of infarction to 18 ± 3.3% and 12.4 ± 3.3%, respectively. In line with that, the neurological deficit score reduced to 2.0 ± 0.7 and 1.0 ± 0.5, respectively ( Figure 6B-D) .
The data indicated that Uro-A treatment protects against ischemic brain injury.
| D ISCUSS I ON
Effective therapeutic intervention for ischemic stroke remains a challenge. Uro-A can cross the blood-brain barrier and has been
shown to protect neuronal cell in the context of Alzheimer's disease. 39 Emerging data indicated Uro-A attenuated ischemic injury in myocardial cells. Autophagy suppresses neuroinflammation 43 and attenuates oxidative stress 44 in ischemic brains. Hence, it is likely that autophagy activation is the primary mechanism underlying the benefits of
Uro-A. It should be noted that it remains unclear how autophagy may contribute to chronic cerebral ischemia. Hence, we did not test the potential neuroprotection of Uro-A in chronic ischemic model in the present study, which should be addressed by further studies.
Autophagy protected against ischemic injury by inducing mitophagy. 8 In addition, Uro-A induced mitophagy in mammal cells and vs sham group, *P < 0.05 and **P < 0.01 vs MCAO group. Data are presented as mean ± SD from seven (n = 7) mice in each group C elegans. 22 We thus hypothesized Uro-A may reduce ischemic neuronal injury by reinforcing mitophagy. However, we did not find mitochondrial loss with Uro-A alone in intact cells nor in OGD/R-treated neuronal cells or in ischemic brain tissues (Figure 4) . Accordingly, 10 µmol/L of Uro-A treatment failed to increase the overlap of autophagosomes with mitochondria, even though autophagosome number was increased in this concentration ( Figure 4A and D) . Therefore, we concluded that Uro-A did not activate mitophagy in ischemic neurons despite that autophagy can be activated. Uro-A induced mitochondrial membrane potential (ΔΨm) loss which further activated mitophagy in a PINK1/Parkin-dependent pathway in muscle cells.
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However, compared with non-neuronal cells, Parkin-mediated mitophagy takes place in a delayed manner in neurons, 45 which might account for little mitophagy activation in intact neurons in the observed time scale. Furthermore, in ischemia/reperfusion-treated neurons, massive ΔΨm loss occurred and subsequently led to extensive mitophagy ( Figure 4) . 9, 13 It thus can be speculated that Uro-A failed to increase the extension of mitophagy in ischemic neurons and in vivo because minimum ΔΨm loss can be further activated by Uro-A. In addition, Uro-A also failed to induce mitochondrial loss in aged cells.
Here we provided evidence doubting the causality of Uro-A on mitophagy induction. Interestingly, Uro-A still induced autophagy regardless of mitophagy inactivation. This phenotype implied that Uro-A may induce autophagy and mitophagy in separate signaling cascades, which need to be addressed in future studies. Our further investigation suggested that Uro-A relieved OGD/R-induced ER stress ( Figure 5 ), which was reversed by autophagy inhibition ( Figure 5E and F). These results were in line with the established role of autophagy in suppressing ER stress. 46, 47 Our previous finding suggested that moderate ER stress during ischemia-reperfusion enhanced mitophagy process by targeting autophagosomes to damaged mitochondria. 35 It is plausible that Uro-A might suppress ER stress induced by OGD/R and MCAO and thus attenuate mitophagy reinforcement.
Furthermore, we found that ER stress suppression could be a critical mechanism underlying the neuroprotective effect of Uro-A, since thapsigargin, an ER stress inducer, abolished the neuroprotection of Uro-A ( Figure 5G ). These observations may make the first link of ER stress with Uro-A-induced autophagy in ischemic neurons.
Taken together, our data advocated the neuroprotective effects of Uro-A against ischemic injury by activating autophagy. Although it was documented that Uro-A induced both autophagy and mitophagy, Uro-A failed to induce mitophagy in ischemic neuronal cells and brains. Alternatively, Uro-A suppressed ER stress by inducing autophagy and prevented neuronal death. Our work provides new insights into the neuroprotective properties of Uro-A, which may give a pharmacological basis for Uro-A as a promising compound for the treatment of cerebral ischemic stroke.
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